Update on Familial Hypercholesterolemia: Diagnosis, Cardiovascular Risk, and Novel Therapeutics

Area of Science:

• Cardiology
• Genetics
• Metabolic Disorders

Background:

• Familial hypercholesterolemia (FH) is an inherited condition causing high LDL-C levels.
• Recent studies indicate a higher prevalence of heterozygous FH.
• Elevated LDL-C significantly increases cardiovascular risk in FH patients.

Purpose of the Study:

• To review the current understanding of FH prevalence and diagnosis.
• To highlight the challenges in achieving LDL-C goals with conventional therapy.
• To discuss the potential of novel therapeutics in managing FH.

Main Methods:

• Review of recent epidemiological studies on FH prevalence.
• Analysis of diagnostic approaches, including clinical criteria and genetic screening.
• Evaluation of current treatment guidelines and therapeutic outcomes.
• Assessment of emerging pharmacotherapies for lipid-lowering.

Main Results:

• Reported prevalence of heterozygous FH is higher than previously documented.
• Clinical diagnosis remains common despite the efficacy of cascade genetic screening.
• Many FH patients do not achieve target LDL-C levels with standard treatments.
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors demonstrate significant LDL-C reduction.

Conclusions:

• Increased recognition of FH prevalence necessitates effective diagnostic and management strategies.
• Achieving LDL-C goals in FH often requires advanced therapeutic options.
• PCSK9 inhibitors represent a promising advancement for improving cardiovascular outcomes in FH.